Reid Robison
Psychiatry · Orem, UTNPI 1760539415
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,538 of the $132,826 with a category attached, or 83.2%. Johnson & Johnson accounts for 97.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $51,362 and has fallen 51.5% since, to $24,924 in 2025. Among psychiatry clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $456.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$129K
- Neurocrine Biosciences, Inc.$2K
- AbbVie$747
- Janssen Scientific Affairs, LLC$381
- Otsuka America Pharmaceutical, Inc.$140
- Lundbeck LLC$110
- plus $580 from 14 others
Across 63 payments — averaging $7078.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$290K
- Merck$66K
- Janssen Research & Development, LLC$25K
- AbbVie$20K
- Sunovion Pharmaceuticals Inc.$14K
- Acadia Pharmaceuticals Inc$11K
- plus $20K from 2 others
What the payments were for
- Speaking & faculty fees$110,53883%
- Travel & lodging$15,89212%
- Food & beverage$6,3965%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 187 | $128,841 |
| Neurocrine Biosciences, Inc. | 21 | $2,028 |
| AbbVie(2 entities) | 31 | $747 |
| Janssen Scientific Affairs, LLC | 5 | $381 |
| Otsuka America Pharmaceutical, Inc. | 9 | $140 |
| Lundbeck LLC | 6 | $110 |
| Vanda Pharmaceuticals Inc. | 4 | $80 |
| Teva Pharmaceuticals USA, Inc. | 6 | $80 |
| Supernus Pharmaceuticals, Inc. | 2 | $72 |
| Alkermes, Inc. | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Ironshore Pharmaceuticals Inc. | 3 | $51 |
| Indivior Inc. | 2 | $37 |
| Alfasigma USA, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Tris Pharma Inc | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,826 in reported general payments places this provider in the 95th percentile of 231 psychiatry providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 77 | $94,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $128,841 | $94,15277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 231 psychiatry providers in Utah.
Other psychiatry in Orem
- David PaulsonOrem$2K
- Michael MeasomSlc$2.2M
- Noel GardnerSalt Lake City$512K
- Thomas RaynerProvo$60K
- Trent HolmbergDraper$32K
- Nathan CurrierRiverton$21K
- Oliver McPhersonBountiful$20K
- Frederick ReimherrSalt Lake City$18K
- Lisa FraleighLogan$8K
- Clark JohnsonSalt Lake City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.